Colorectal cancer prevention

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 378-391

  Hawk, Ernest T ^a   Levin, Bernard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CALCIUM CARBONATE; CELECOXIB; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ISPAGULA; LYSINE ACETYLSALICYLATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SELENIUM; URSODEOXYCHOLIC ACID;

ADENOMATOUS POLYP; BARIUM ENEMA; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGITAL RECTAL EXAMINATION; DRUG MECHANISM; DYSPLASIA; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OCCULT BLOOD; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIGMOIDOSCOPY; COLON POLYP; COLORECTAL TUMOR; FEMALE; FORECASTING; MALE; PATIENT SELECTION; PRECANCER; RISK;

ADENOMATOUS POLYPS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CLINICAL TRIALS; COLONIC POLYPS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; FEMALE; FORECASTING; HUMANS; MALE; PATIENT SELECTION; PRECANCEROUS CONDITIONS; RISK;

EID: 13744260035     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.097     Document Type: Review

References (167)

1. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer, 2004. CA Cancer J Clin 54:41-52, 2004
2. Spann S, Levin B, Rozen P, et al: Colorectal cancer: How big is the problem, why prevent it and how might it present? In Rozen P, Young G, Levin B, et al (eds): Colorectal Cancer in Clinical Practice: Prevention, Early Detection and Management. London, Martin Dunitz Ltd, 2002, pp 1-13
3. Smith RA, Cokkinides V, von Eschenbach AC, et al: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 52:8-22, 2002
4. Winawer SJ, Fletcher RH, Rex D, et al: Colorectal cancer screening and surveillance: clinical guidelines rationale-update based on new evidence. Gastroenterology 124:544-560, 2003
5. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1998
6. Jass JR: Pathogenesis of colorectal cancer. Surg Clin North Am 82:891-904, 2002
7. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
8. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
9. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168-174, 2000
10. Takayama T, Ohi M, Hayashi T, et al: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121:599-611, 2001
11. Ilyas M, Straub J, Tomlinson IP, et al: Genetic pathways in colorectal and other cancers. Eur J Cancer 35:1986-2002, 1999
12. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699-2702, 1976
13. Kelloff GJ, Boone CW, Crowell JA, et al: Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25:1-14, 1996
14. Atkin WS, Morson BC, Cuzick J: Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658-662, 1992
15. Simon JB: Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 88:820-837, 1985
16. Macrae FA, St John DJ: Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers and adenomas. Gastroenterology 82:891-898, 1982
17. Mandel JS, Bond JH, Church TR, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328:1365-1371, 1993
18. Hardcastle JD, Chamberlain JO, Robinson MHE, et al: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348:1472-1477, 1996
19. Scholefield JH, Moss S, Sufi F, et al: Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50:840-844, 2002
20. Kronberg O, Fenger C, Olsen J, et al: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348:1467-1471, 1996
21. Jorgensen OD, Kronborg O, Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50:29-32, 2002
22. Ederer F, Church TR, Mandel JS: Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst 89:1423-1428, 1997
23. Towler BP, Irwig L, Glasziou P, et al: Screening for colorectal cancer using the faecal occult blood test, Hemoccult (Cochrane Review), In: The Cochrane Library, Issue 4. Chichester UK, John Wiley & Sons, Ltd, 2004
24. Mandel JS, Church TR, Bond JH, et al: The effect of fecal occult blood screening on the incidence of colorectal cancer. N Engl J Med 343:1603-1607, 2000
25. Young GP, Rozen P, Levin B: How should we screen for early colorectal neoplasia? In Rozen P, Young G, Levin B, et al (eds): Colorectal Cancer in Clinical Practice: Prevention, Early Detection and Management. London, Martin Dunitz Ltd, 2002, pp 77-99
26. Levin B, Brooks S, Smith RA, et al: Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult tests and stool screening using molecular markers. CA Cancer J Clin 53:44-55, 2003
27. Young GP, St. John DB, Cole SR, et al: Prescreening evaluation of a brush-based faecal immunochemical test for haemoglobin. J Med Screen 10:123-128, 2003
28. Tedesco JF, Waye JD, Avella JR, et al: Diagnostic implications of the spatial distribution of colonic mass lesions (polyps and cancers): a prospective colonoscopic study. Gastrointest Endosc 26:95-97, 1980
29. Shinya H, Wolff WI: Morphology, anatomic distribution and cancer potential of colonic polyps: an analysis of 7000 polyps endoscopically removed. Ann Surg 190:679-683, 1979
30. Winawer SJ, Zauber AG, O'Brien MJ, et al: The National Polyp Study. 1. Design, methods and characteristics of patients with newly diagnosed polyps. The National Polyp Study Workgroup. Cancer 70:1236-1245, 1992 (suppl 5)
31. Grossman S, Milos ML, Tekawa IS, et al: Colonoscopic screening of persons with suspected risk factors for colon cancer. II. Past history of colorectal neoplasms. Gastroenterology 96:299-306, 1989
32. Selby JV, Friedman GD, Quesenberry CP, Jr., et al: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326:653-657, 1992
33. Newcomb PA, Norfleet RG, Storer BE: Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 84:1572-1575, 1992
34. Schoen RE, Pinsky RF, Weissfeld JL, et al: Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 290:41-48, 2003
35. UK Flexible Sigmoidoscopy Screening Trial Investigators: Single flexible sigmoidoscopy screening to prevent colorectal cancer: Baseline findings of a UK multicentre randomized trial. Lancet 359:1291-1300, 2002
36. Thiis-Evenson E, Hoff GS, Sauar J, et al: Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 34:414-420, 1999
37. Segnan N, Senore C, Andreoni B, et al: Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"- SCORE. J Natl Cancer Inst 94:1763-1772, 2002
38. Winawer SJ, Zauber AG, Ho MN, et al: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977-1981, 1993
39. Hixson LJ, Femerty MB, Sampliner RE, et al: Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 82:1769-1772, 1990
40. Bernstein MA, Feczko PJ, Halpert RD, et al: Distribution of colonic polyps: increased incidence of proximal lesions in older patients. Radiology 155:35-38, 1985
41. Lieberman DA, Weiss DG, Bond JH, et al: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343:162-168, 2000
42. Imperiale TF, Wagner DR, Lin CY, et al: Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 343:169-174, 2000
43. Pickhardt PJ, Choi JR, Hwang I, et al: Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 349:2191-2200, 2003
44. Cotton PB, Duralski VL, Pineau BC, et al: Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonography for detection of colorectal neoplasia. JAMA 291:1713-1719, 2004
45. Ransohoff D: Virtual colonoscopy - what it can do vs. what it will do. JAMA 291:1772-1774, 2004
46. Dong SM, Traverso G, Johnson C, et al: Detecting colorectal cancer in stool using multiple genetic targets. J Natl Cancer Inst 93:858-865, 2001
47. Traverso G, Shuber A, Levin B, et al: Detection of APC mutations in fecal DNA of patients with colorectal tumors. N Engl J Med 346:311-320, 2002
48. Traverse G, Shuber A, Olsson L, et al: Detection of proximal colorectal cancer through the analysis of fecal DNA. Lancet 359:403-404, 2002
49. Wagner JL, Tunis S, Brown M, et al: The cost-effectiveness of colorectal cancer screening in average-risk adults, In Young G, Levin B, Rozen A (eds): Prevention and Early Detection of Colorectal Cancer. London, WB Saunders, 1996, pp 321-356
50. Levin B: Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention. J Natl Cancer Inst 95:697-699, 2003
51. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314-346, 2002
52. Winawer SJ, Stewart ET, Zauber AG, et al: A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 342:1766-1772, 2000
53. Wahrendorf J, Robra BP, Wiebelt H, et al: Effectiveness of colorectal cancer screening: results from a population-based case-control evaluation in Saarland, Germany. Eur J Cancer Prev 2:221-227, 1993
54. Muller AD, Sonnenberg A: Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 123:904-910, 1995
55. Muller AD, Sonnenberg A: Protection by endoscopy against death from colorectal cancer. A case- control study among veterans. Arch Intern Med 155:1741-1748, 1995
56. Corpet DE, Tache S: Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43:1-21, 2002
57. Takayama T, Katsuki S, Takahashi Y, et al: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339:1277-1284, 1998
58. Hawk ET, Viner JL, Umar A, et al: Cancer and the cyclooxygenase enzyme: Implications for the treatment and prevention. Am J Cancer 2:27-55, 2003
59. Shpitz B, Klein E, Buklan G, et al: Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 52:1598-1601, 2003
60. Villavicencio RT, Rex DK: Colonic adenomas: prevalence and incidence rates, growth rates, and miss rates at colonoscopy. Semin Gastrointest Dis 11:185-193, 2000
61. Peterson KA, DiSario JA: Secondary prevention: screening and surveillance of persons at average and high risk for colorectal cancer. Hematol Oncol Clin North Am 16:841-865, 2002
62. Giardiello FM, Yang VW, Hylind LM, et al: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054-1059, 2002
63. Giardiello FM: Sulindac and polyp regression. Cancer Metastasis Rev 13:279-283, 1994
64. Hawk E, Viner JL, Lawrence JA: Biomarkers as surrogates for cancer development. Curr Oncol Rep 2:242-250, 2000
65. Kelloff GJ, Johnson JR, Crowell JA, et al: Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4:1-10, 1995
66. Kelloff GJ: Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 78:199-334, 2000
67. Cancer Prevention Study II: The American Cancer Society Prospective Study. Stat Bull Metrop Insur Co 73:21-29, 1992
68. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991
69. Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995
70. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
71. Greenberg ER, Baron JA, Tosteson TD, et al: A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 331:141-147, 1994
72. Alberts DS, Martinez ME, Roe DJ, et al: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 342:1156-1162, 2000
73. Schatzkin A, Lanza E, Corle D, et al: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342:1149-1155, 2000
74. Corpet DE, Pierre F: Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12:391-400, 2003
75. Moser AR, Pitot HC, Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247:322-324, 1990
76. Sasai H, Masaki M, Wakitani K: Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis 21:953-958, 2000
77. Williamson SL, Kartheuser A, Coaker J, et al: Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis 20:805-810, 1999
78. Reitmair AH, Schmits R, Ewel A, et al: MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat Genet 11:64-70, 1995
79. Edelmann W, Yang K, Umar A, et al: Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91:467-477, 1997
80. Edelmann W, Umar A, Yang K, et al: The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 60:803-807, 2000
81. Prolla TA, Baker SM, Harris AC, et al: Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 18:276-279, 1998
82. Baron JA, Beach M, Mandel JS, et al: Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101-107, 1999
83. Li H, Kramer PM, Lubet RA, et al: Effect of calcium on azoxymethane-induced aberrant crypt foci and cell proliferation in the colon of rats. Cancer Lett 124:39-46, 1998
84. Wargovich MJ, Allnutt D, Palmer C, et al: Inhibition of the promotional phase of azoxymethane-induced colon carcinogenesis in the F344 rat by calcium lactate: effect of simulating two human nutrient density levels. Cancer Lett 53:17-25, 1990
85. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003
86. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883-890, 2003
87. Craven PA, DeRubertis FR: Effects of aspirin on 1,2-dimethylhydrazine- induced colonic carcinogenesis. Carcinogenesis 13:541-546, 1992
88. Barnes CJ, Lee M: Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114:873-877, 1998
89. Davis AE, Patterson F: Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med 24:301-303, 1994
90. Reddy BS, Rao CV, Rivenson A, et al: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14:1493-1497, 1993
91. Shpitz B, Bomstein Y, Kariv N, et al: Chemopreventive effect of aspirin on growth of aberrant crypt foci in rats. Int J Colorectal Dis 13:169-172, 1998
92. Jacoby RF, Seibert K, Cole CE, et al: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044, 2000
93. Reddy BS, Hirose Y, Lubet R, et al: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293-297, 2000
94. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
95. Umar A, Viner JL, Richmond E, et al: Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7:2-26, 2002
96. Faivre J, Bonithon-Kopp C: Effect of fibre and calcium supplementation on adenoma recurrence and growth. IARC Sci Pubi 156:457-461, 2002
97. Clark LC, Combs GF, Jr., Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996
98. Benamouzig R, Deyra J, Martin A, et al: Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 125:328-336. 2003
99. Bussey HJ, DeCosse JJ, Deschner EE, et al: A randomized trial of ascorbic acid in polyposis coli. Cancer 50:1434-1439, 1982
100. Walker AR, Burkitt DP: Colonic cancer-hypotheses of causation, dietary prophylaxis, and future research. Am J Dig Dis 21:910-917, 1976
101. Wynder EL: The epidemiology of large bowel cancer. Cancer Res 35:3388-3394, 1975
102. Slattery ML: Diet, lifestyle, and colon cancer. Semin Gastrointest Dis 11:142-146, 2000
103. Steinmetz KA, Potter JD: Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 96:1027-1039, 1996
104. Lamson DW, Brignall MS: Natural agents in the prevention of cancer. Part 1: Human chemoprevention trials. Altern Med Rev 6:7-19, 2001
105. Lamson DW, Brignall MS: Natural agents in the prevention of cancer, part two: preclinical data and chemoprevention for common cancers. Altern Med Rev 6:167-187, 2001
106. MacLennan R, Macrae F, Bain C, et al: Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 87:1760-1766, 1995
107. DeCosse JJ, Miller HH, Lesser 7L: Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 81:1290-1297, 1989
108. Hofstad B, Almendingen K, Vatn M, et al: Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 59:148-156, 1998
109. Malila N, Virtamo J, Virtanen M, et al: The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prev 8:489-493, 1999
110. Albanes D, Malila N, Taylor PR, et al: Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 11:197-205, 2000
111. Gann PH, Manson JE, Glynn RJ, et al: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220-1224, 1993
112. Alberts DS, Martinez ME, Roe D, et al: Proving the bile acid hypothesis for colon carcinogenesis: Mature results from a phase III chemoprevention trial of ursodeoxycholic acid versus placebo to prevent colorectal adenoma recurrence. Proc Am Soc Clin Oncol 22:91, 2003 (abstr 363)
113. Riboli E: Nutrition and cancer of the respiratory and digestive tract: results from observational and chemoprevention studies. Eur J Cancer Prev 5:9-17, 1996 (suppl 2)
114. Shamberger RJ, Tytko SA, Willis CE Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality Arch Environ Health 31:231-235, 1976
115. Knekt P, Aromaa A, Maatela J, et al: Serum vitamin E, serum selenium and the risk of gastrointestinal cancer. Int J Cancer 42:846-850, 1988
116. Knekt P, Aromaa A, Maatela J, et al: Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 82:864-868, 1990
117. Clark LC, Hixson LJ, Combs GF, Jr., et al: Plasma selenium concentration predicts the prevalence of colorectal adenomatous polyps Cancer Epidemiol Biomarkers Prev 2:41-46, 1993
118. Nelson RL, Davis FG, Sutter E, et al: Serum selenium and colonic neoplastic risk. Dis Colon Rectum 38:1306-1310, 1995
119. Giovannucci E, Goldin B: The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 66:15645-15715, 1997
120. Narisawa T, Magadia NE, Weisburger JH, et al: Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 53:1093-1097, 1974
121. Bautista D, Obrador A, Moreno V, et al: Kiras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 6:57-61, 1997
122. Martinez ME, Willett WC: Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 7:163-168, 1998
123. Bonithon-Kopp C, Kronborg O, Giacosa A, et al: Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organization Study Group. Lancet 356:1300-1306, 2000
124. Design of the Women's Health Initiative clinical trial and observational study: The Women's Health Initiative Study Group. Control Clin Trials 19:61-109, 1998
125. Borgelt L, Umland E: Benefits and challenges of hormone replacement therapy. J Am Pharrn Assoc (Wash) 40:530-531, 2000
126. MacLennan SC, MacLennan AH, Ryan P: Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 162:491-493, 1995
127. Grodstein F, Martinez ME, Platz EA, et al: Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128:705-712, 1998
128. Calle EE, Miracle-McMahill HL, Thun MJ, et al: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87:517-523, 1995
129. Troisi R, Schairer C, Chow WH, et al: Reproductive factors, oral contraceptive use, and risk of colorectal cancer. Epidemiology 8:75-79, 1997
130. Potter JD, Bostick RM, Grandits GA, et al: Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: The Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 5:779-784, 1996
131. Nanda K, Bastian LA, Hasselblad V, et al: Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93:880-888, 1999
132. Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004
133. Guo JY, Li X, Browning JD, Jr., et al: Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 134:179-182, 2004
134. Jaffe BM: Prostaglandins and cancer: an update. Prostaglandins 6:453-461, 1974
135. Sheehan KM, Sheahan K, O'Donoghue DP, et al: The relationship between cvclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257, 1999
136. Ristimaki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635, 2002
137. Gaffney DK, Holden J, Davis M, et al: Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 49:1213-1217, 2001
138. Buskens CJ, Van Rees BP, Sivula A, et al: Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122:1800-1807, 2002
139. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867, 2001
140. Marnett LJ, DuBois RN: COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42:55-80, 2002
141. Lehmann JM, Lenhard JM, Oliver BB, et al: Peroxisome proliferator- activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410, 1997
142. Hsu AL, Ching TT, Wang DS, et al: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275:11397-11403, 2000
143. Waskewich C, Blumenthal RD, Li H, et al: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62:2029-2033, 2002
144. Shureiqi I, Chen D, Lotan R, et al: 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res 60:6846-6850, 2000
145. Shureiqi I, Jiang W, Zuo X, et al: The 15-lipoxygenase-1 product 13-S-hydroxyocta-decadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100:9968-9973, 2003
146. Cruz-Correa M, Hylind LM, Romans KE, et al: Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 122:641-645, 2002
147. Burn J, Chapman PD, Bishop DT, et al: Results of the CAPP1 Study: Aspirin and resistant starch are beneficial in familial adenomatous polyposis. Fam Cancer 2:42, 2003
148. Muir K, Logan R, Armitage N: The United Kingdom colorectal adenoma prevention trial (ukCAP): Trial descripion and recruited patient characteristics, In American Association for Cancer Research (ed): Frontiers in Cancer Prevention Research. Boston, AACR, 2002, pp 137
149. Rexrode KM, Lee IM, Cook NR, et al: Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9:19-27, 2000
150. Phillips RK, Wallace MH, Lynch PM, et al: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50:857-860, 2002
151. Sinicrope FA, Half EO, Morris JS, et al: Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in Familial Adenomatous Polyposis (FAP) patients. Cancer Epidemiol Biomarkers Prev 13:920-927, 2004
152. Xiao Z, Luke BT, Izmirlian G, et al: Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64:2904-2909, 2004
153. Hallak A, Alon-Baron L, Shamir R, et al: Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998-2002, 2003
154. Corpet DE, Tache S: Ranking chemopreventive agents on rat colon carcinogenesis. IARC Sci Publ 156:381-384, 2002
155. Viner JL, Umar A, Hawk ET: Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 31:971-999, 2002
156. Corpet DE, Parnaud G, Delverdier M, et al: Consistent and fast inhibition of colon carcinogenesis by polyethylene glycol in mice and rats given various carcinogens. Cancer Res 60:3160-3164, 2000
157. Zhu J, Song X, Lin HP, et al: Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745-1757, 2002
158. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024-1028, 2000
159. Goss KJ, Brown PD, Matrisian LM: Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78:629-635, 1998
160. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, et al: Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 24:177-187, 1999
161. Armstrong WB, Kennedy AR, Wan XS, et al: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9:43-47, 2000
162. Armstrong WB, Kennedy AR, Wan XS, et al: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684-4691, 2000
163. Lippman SM, Matrisian LM: Protease inhibitors in oral carcinogenesis and chemoprevention. Clin Cancer Res 6:4599-4603, 2000
164. Green RJ, Metlay JP, Propert K, et al: Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 136:261-269, 2002
165. Schoen RE, Pinsky PF, Weissfeld JL, et al: Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 290:41-48, 2003
166. Umar A, Viner JL, Hawk ET: The future of colon cancer prevention. Ann N Y Acad Sci 952:88-108, 2001
167. Woolf SH: The Best Screening Test for Colorectal Cancer-A Personal Choice. N Engl J Med 343:1641-1643, 2000